Calliditas Therapeutics AB (publ) (NASDAQ Stockholm: CALTX), a specialty pharmaceutical company based in Stockholm, Sweden, announced yesterday that it has named Dr Frank Bringstrup as its new vice president regulatory affairs, effective 1 February 2019.
As a member of the company's management team, Bringstrup will have a leading role in the regulatory discussions and approval process for the company's pivotal clinical phase three study, NEFIGARD, in patients with IgA nephropathy (IgAN).
Dr Bringstrup has more than 17 years experience in the pharmaceutical industry in regulatory affairs and health authority interactions. He worked in various positions at Novo Nordisk A/S, most recently as its senior global regulatory lead. During his time at Novo Nordisk, he led the strategic regulatory input for the orphan drug NovoEight all the way from phase one to phase three with five parallel MAAs and NDAs and five major approvals gained in a 15-month period. He has a wealth of experience of Regulatory Affairs in the US, EU, Japanese and international markets, and was, among other projects, responsible for overseeing the lifecycle development for new indications for the orphan drug NovoSeven, a recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting haemostasis by activating the extrinsic pathway of the coagulation cascade.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study